Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Urology Reports
Published in: Current Urology Reports 5/2013

01-10-2013 | Surgical Techniques (J Cadeddu and A Stenzl, Section Editors)

Reducing Morbidity of Pelvic and Retroperitoneal Lymphadenectomy

Authors: Mark W. Ball, Michael A. Gorin, Mohamad E. Allaf

Published in: Current Urology Reports | Issue 5/2013

Login to get access

Abstract

Lymphadenectomy is utilized in both pelvic and retroperitoneal oncological surgery as a means to eradicate locoregional disease, improve staging accuracy and guide adjuvant therapy. However, pelvic and retroperitoneal lymphadenectomy have the potential for morbidity including lymphatic injury, vascular injury, thromboembolic events and neurologic injury. Across the spectrum of urologic malignancies, the evidence supporting both the necessity and the extent of lymphadenectomy varies considerably. Awareness of the potential for injury and ways to avoid and manage the most common complications is necessary to decrease the morbidity associated with these procedures.
Literature
1.
Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999;341(24):1781–8.PubMedCrossRef
2.
Herr HW, Bochner BH, Dalbagni G, Donat SM, Reuter VE, Bajorin DF. Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J Urol. 2002;167(3):1295–8.PubMedCrossRef
3.
Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19(3):666–75.PubMed
4.
Dhar NB, Klein EA, Reuther AM, Thalmann GN, Madersbacher S, Studer UE. Outcome after radical cystectomy with limited or extended pelvic lymph node dissection. J Urol. 2008;179(3):873–8. discussion 878.PubMedCrossRef
5.
• Blom JH, van Poppel H, Marechal JM, Jacqmin D, Schroder FH, de Prijck L, et al. Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur Urol. 2009;55(1):28–34. This randomized trial represents the only level 1 evidence in the urological literature on the benefit of LND, and shows no survival benefit of LND at the time of radical nephrectomy.PubMedCrossRef
6.
Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrle R. Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965 to 1989): modifications of technique and impact on ejaculation. J Urol. 1993;149(2):237–43.PubMed
7.
Heidenreich A, Thuer D, Polyakov S. Postchemotherapy retroperitoneal lymph node dissection in advanced germ cell tumours of the testis. Eur Urol. 2008;53(2):260–72.PubMedCrossRef
8.
Allaf ME, Palapattu GS, Trock BJ, Carter HB, Walsh PC. Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. J Urol. 2004;172(5 Pt 1):1840–4.PubMedCrossRef
9.
Musch M, Klevecka V, Roggenbuck U, Kroepfl D. Complications of pelvic lymphadenectomy in 1,380 patients undergoing radical retropubic prostatectomy between 1993 and 2006. J Urol. 2008;179(3):923–8. discussion 928–9.PubMedCrossRef
10.
Swanson GP, Thompson IM, Basler J. Current status of lymph node-positive prostate cancer: incidence and predictors of outcome. Cancer. 2006;107(3):439–50.PubMedCrossRef
11.
Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology. 2001;58(6):843–8.PubMedCrossRef
12.
Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA. 1997;277(18):1445–51.PubMedCrossRef
13.
D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969–74.PubMedCrossRef
14.
Kawakami J, Meng MV, Sadetsky N, Latini DM, Duchane J, Carroll PR, et al. Changing patterns of pelvic lymphadenectomy for prostate cancer: results from CaPSURE. J Urol. 2006;176(4 Pt 1):1382–6.PubMedCrossRef
15.
NCCN Clinical Practice Guidelines in Oncology, Prostate Cancer, Version 2.2013. Accessed 3/11/2013.
16.
Tsukamoto T, Kitamura H, Takahashi A, Masumori N. Treatment of invasive bladder cancer: lessons from the past and perspective for the future. Jpn J Clin Oncol. 2004;34(6):295–306.PubMedCrossRef
17.
Soloway MS, Lopez AE, Patel J, Lu Y. Results of radical cystectomy for transitional cell carcinoma of the bladder and the effect of chemotherapy. Cancer. 1994;73(7):1926–31.PubMedCrossRef
18.
Leissner J, Ghoneim MA, Abol-Enein H, Thuroff JW, Franzaring L, Fisch M, et al. Extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter study. J Urol. 2004;171(1):139–44.PubMedCrossRef
19.
Solberg A, Angelsen A, Bergan U, Haugen OA, Viset T, Klepp O. Frequency of lymphoceles after open and laparoscopic pelvic lymph node dissection in patients with prostate cancer. Scand J Urol Nephrol. 2003;37(3):218–21.PubMedCrossRef
20.
Keegan KA, Cookson MS. Complications of pelvic lymph node dissection for prostate cancer. Curr Urol Rep. 2011;12(3):203–8.PubMedCrossRef
21.
Gotto GT, Yunis LH, Guillonneau B, Touijer K, Eastham JA, Scardino PT, et al. Predictors of symptomatic lymphocele after radical prostatectomy and bilateral pelvic lymph node dissection. Int J Urol. 2011.
22.
Pepper RJ, Pati J, Kaisary AV. The incidence and treatment of lymphoceles after radical retropubic prostatectomy. BJU Int. 2005;95(6):772–5.PubMedCrossRef
23.
Alago Jr W, Deodhar A, Michell H, Sofocleous CT, Covey AM, Solomon SB, et al. Management of postoperative lymphoceles after lymphadenectomy: percutaneous catheter drainage with and without povidone-iodine sclerotherapy. Cardiovasc Intervent Radiol. 2013;36(2):466–71.PubMedCrossRef
24.
Treiyer A, Haben B, Stark E, Breitling P, Steffens J. Uni- vs. multiloculated pelvic lymphoceles: differences in the treatment of symptomatic pelvic lymphoceles after open radical retropubic prostatectomy. Int Braz J Urol. 2009;35(2):164–9. discussion 170.PubMedCrossRef
25.
Clark T, Parekh DJ, Cookson MS, Chang SS, Smith Jr ER, Wells N, et al. Randomized prospective evaluation of extended versus limited lymph node dissection in patients with clinically localized prostate cancer. J Urol. 2003;169(1):145–7. discussion 147–8.PubMedCrossRef
26.
Briganti A, Chun FK, Salonia A, Suardi N, Gallina A, Da Pozzo LF, et al. Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer. Eur Urol. 2006;50(5):1006–13.PubMedCrossRef
27.
Catalona WJ, Kadmon D, Crane DB. Effect of mini-dose heparin on lymphocele formation following extraperitoneal pelvic lymphadenectomy. J Urol. 1980;123(6):890–2.PubMed
28.
Lee JY, Diaz RR, Cho KS, Yu HS, Chung JS, Ham WS, et al. Lymphocele after extraperitoneal robot-assisted radical prostatectomy: A propensity score-matching study. Int J Urol. 2013.
29.
Kropfl D, Krause R, Hartung R, Pfeiffer R, Behrendt H. Subcutaneous heparin injection in the upper arm as a method of avoiding lymphoceles after lymphadenectomies in the lower part of the body. Urol Int. 1987;42(6):416–23.PubMedCrossRef
30.
• Orvieto MA, Coelho RF, Chauhan S, Palmer KJ, Rocco B, Patel VR. Incidence of lymphoceles after robot-assisted pelvic lymph node dissection. BJU Int. 2011;108(7):1185–90. This study demonstrated that lymphoceles are common even after transperitoneal PLND at the time of radical prostatectomy. The authors provide evidence disputing the thought that the larger space of the peritoneum leads to less lymphocele formation compared to surgery confined to the extraperitoneal space.PubMedCrossRef
31.
Stone NN, Stock RG, Unger P. Laparoscopic pelvic lymph node dissection for prostate cancer: comparison of the extended and modified techniques. J Urol. 1997;158(5):1891–4.PubMedCrossRef
32.
Lallas CD, Pe ML, Thumar AB, Chandrasekar T, Lee FC, McCue P, et al. Comparison of lymph node yield in robot-assisted laparoscopic prostatectomy with that in open radical retropubic prostatectomy. BJU Int. 2011;107(7):1136–40.PubMedCrossRef
33.
Loeb S, Partin AW, Schaeffer EM. Complications of pelvic lymphadenectomy: do the risks outweigh the benefits? Rev Urol. 2010;12(1):20–4.PubMed
34.
Williams SK, Rabbani F. Complications of lymphadenectomy in urologic surgery. Urol Clin North Am. 2011;38(4):507–18. vii.PubMedCrossRef
35.
Burnett AL, Brendler CB. Femoral neuropathy following major pelvic surgery: etiology and prevention. J Urol. 1994;151(1):163–5.PubMed
36.
Scarpa RM, Carrieri G, Gussoni G, Tubaro A, Conti G, Pagliarulo V, et al. Clinically overt venous thromboembolism after urologic cancer surgery: results from the @RISTOS Study. Eur Urol. 2007;51(1):130–5. discussion 136.PubMedCrossRef
37.
Rice KR, Brassell SA, McLeod DG. Venous thromboembolism in urologic surgery: prophylaxis, diagnosis, and treatment. Rev Urol. 2010;12(2–3):e111–24.PubMed
38.
Van Hemelrijck M, Garmo H, Holmberg L, Bill-Axelson A, Carlsson S, Akre O, et al. Thromboembolic events following surgery for prostate cancer. Eur Urol. 2013;63(2):354–63.PubMedCrossRef
39.
Clement C, Rossi P, Aissi K, Barthelemy P, Guibert N, Auquier P, et al. Incidence, risk profile and morphological pattern of lower extremity venous thromboembolism after urological cancer surgery. J Urol. 2011;186(6):2293–7.PubMedCrossRef
40.
Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):381S–453S.PubMedCrossRef
41.
• Eifler JB, Levinson AW, Hyndman ME, Trock BJ, Pavlovich CP. Pelvic lymph node dissection is associated with symptomatic venous thromboembolism risk during laparoscopic radical prostatectomy. J Urol. 2011;185(5):1661–5. This study demonstrated that PLND doubles the risk of venous thromboembolism during laparoscopic radical prostatectomy.PubMedCrossRef
42.
Forrest JB, Clemens JQ, Finamore P, Leveillee R, Lippert M, Pisters L, et al. AUA Best Practice Statement for the prevention of deep vein thrombosis in patients undergoing urologic surgery. J Urol. 2009;181(3):1170–7.PubMedCrossRef
43.
Feng T, Patel HD, Allaf ME. Pudendal artery pseudoaneurysm after robot-assisted laparoscopic radical prostatectomy. Urology. 2013;81(1):e5–6.PubMedCrossRef
44.
Donohue JP, Zachary JM, Maynard BR. Distribution of nodal metastases in nonseminomatous testis cancer. J Urol. 1982;128(2):315–20.PubMed
45.
Donohue JP. Nerve-sparing retroperitoneal lymphadenectomy for testis cancer. Evolution of surgical templates for low-stage disease. Eur Urol. 1993;23 Suppl 2:44–6.PubMed
46.
Baniel J, Foster RS, Rowland RG, Bihrle R, Donohue JP. Complications of primary retroperitoneal lymph node dissection. J Urol. 1994;152(2 Pt 1):424–7.PubMed
47.
Baniel J, Foster RS, Rowland RG, Bihrle R, Donohue JP. Complications of post-chemotherapy retroperitoneal lymph node dissection. J Urol. 1995;153(3 Pt 2):976–80.PubMed
48.
Evans JG, Spiess PE, Kamat AM, Wood CG, Hernandez M, Pettaway CA, et al. Chylous ascites after post-chemotherapy retroperitoneal lymph node dissection: review of the M. D. Anderson experience. J Urol. 2006;176(4 Pt 1):1463–7.PubMedCrossRef
49.
Mullins JK, Pierorazio PM, Hyams ES, Mitchell SE, Allaf ME. Lymphangiography with sclerotherapy: a novel therapy for refractory chylous ascites. Can J Urol. 2012;19(3):6250–4.PubMed
50.
Jewett MA, Kong YS, Goldberg SD, Sturgeon JF, Thomas GM, Alison RE, et al. Retroperitoneal lymphadenectomy for testis tumor with nerve sparing for ejaculation. J Urol. 1988;139(6):1220–4.PubMed
51.
Donohue JP, Foster RS, Rowland RG, Bihrle R, Jones J, Geier G. Nerve-sparing retroperitoneal lymphadenectomy with preservation of ejaculation. J Urol. 1990;144(2 Pt 1):287–91. discussion 291–2.PubMed
52.
Abouassaly R, Klein EA, Raghavan D. Complications of surgery and chemotherapy for testicular cancer. Urol Oncol. 2005;23(6):447–55.PubMedCrossRef
53.
Bhayani SB, Ong A, Oh WK, Kantoff PW, Kavoussi LR. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular cancer: a long-term update. Urology. 2003;62(2):324–7.PubMedCrossRef
54.
Guzzo TJ, Gonzalgo ML, Allaf ME. Laparoscopic retroperitoneal lymph node dissection with therapeutic intent in men with clinical stage I nonseminomatous germ cell tumors. J Endourol. 2010;24(11):1759–63.PubMedCrossRef
55.
Hyams ES, Pierorazio P, Proteek O, Sroka M, Kavoussi LR, Allaf ME. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumor: a large single institution experience. J Urol. 2012;187(2):487–92.PubMedCrossRef
Metadata
Title
Reducing Morbidity of Pelvic and Retroperitoneal Lymphadenectomy
Authors
Mark W. Ball
Michael A. Gorin
Mohamad E. Allaf
Publication date
01-10-2013
Publisher
Springer US
Published in
Current Urology Reports / Issue 5/2013
Print ISSN: 1527-2737
Electronic ISSN: 1534-6285
DOI
https://doi.org/10.1007/s11934-013-0350-9

Other articles of this Issue 5/2013

Current Urology Reports 5/2013 Go to the issue

Testis and Penile Cancer (M Manoharan and J Sheinfeld, Section Editors)

Controversies in the Management of Stage 1 Non-Seminomatous Germ Cell Tumors

Testis and Penile Cancer (M Manoharan and J Sheinfeld, Section Editors)

Contemporary Management of Stage I and II Seminoma

Surgical Techniques (J Cadeddu and A Stenzl, Section Editors)

Zero-Ischemia Minimally Invasive Partial Nephrectomy

Surgical Techniques (J Cadeddu and A Stenzl, Section Editors)

Laparoendoscopic Single-Site Surgery in Kidney Surgery: Clinical Experience and Future Perspectives

Surgical Techniques (J Cadeddu and A Stenzl, Section Editors)

Cell-Based Therapy for the Deficient Urinary Sphincter

Lower Urinary Tract Symptoms and Voiding Dysfunction (G Badlani and H Goldman, Section Editors)

Retropubic Versus Transobturator Slings—Are the Outcomes Changing with Time?